Zheng showed that high PD-1 expression on peripheral CD4+ T cells is associated with inferior clinical response in non-small-cell lung carcinoma patients who received anti-PD-L1 treatment [29]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.